Black Diamond Therapeutics (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.
Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.
The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.
Chief People Officer Elizabeth Montgomery is also leaving the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.